Late-Breaking
 Join or renew your AHA/ASA Professional Membership by Sept. 26 to save on registration for Scientific Sessions 2012. |
 Abstract submission will be open from April 17 through June 6, 2012. |
|
Jump to: Late-Breaking Clinical Trials | Clinical Science: Special Reports
You won’t want to miss the Late-Breaking Clinical Trial and Clinical Science: Special Reports sessions covering the following important topics:
- Atrial Fibrillation
- Health Services Research
- Interventional Cardiology/Surgery
- Prevention
- Regenerative Medicine
- Strategies of Care
- Thrombosis
| LATE-BREAKING CLINICAL TRIALS | View in Program Planner | |
| Sunday, Nov. 13, 2011 LBCT.01 | 3:45 - 5:13 p.m. | West Hall B4 | |
| TRIAL NAME | TRIAL DESCRIPTION |
| Intracoronary Compared with Intravenous Bolus Abciximab Application During Primary Percutaneous Coronary Intervention: AIDA STEMI Trial | The trial was designed to show that intracoronary abciximab bolus in comparison to standard intravenous application will improve the outcome of patients undergoing primary PCI in STEMI with respect to death, reinfarction and congestive heart failure |
| Abciximab Plus Unfractionated Heparin versus Bivalirudin in Patients with Non-ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention. The ISAR-REACT 4 Randomized Trial | This trial was designed to comparatively evaluate the efficacy and safety of bivalirudin vs. abciximab plus heparin in patients with NSTEMI undergoing PCI. |
| Extended Anticoagulant Prophylaxis in Initially Hospitalized Medically Ill Patients: Results of the ADOPT (Apixaban Dosing to Optimize Protection from Thrombosis) Trial | The ADOPT Trial of 6,528 randomized subjects was designed to evaluate whether 1 month of apixaban 2.5 mg twice daily reduced the incidence of venous thromboembolism in medically ill patients compared with a minimum of 6 days of enoxaparin 40 mg daily. |
| The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA•CER) Trial | The TRACER trial is evaluating the novel PAR-1 inhibitor, vorapaxar, in patients with acute coronary syndromes. |
| Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 51 (ATLAS ACS 2-TIMI 51) Trial: A Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subjects with Acute Coronary Syndrome | The ATLAS ACS 2-TIMI 51 trial was designed to test if treatment with rivaroxaban in addition to standard care is superior to treatment with placebo in addition to standard care in reducing the risk of cardiovascular (CV) death, myocardial infarction (MI) or stroke in subjects with a recent ACS. |
| Monday, Nov. 14, 2011 LBCT.02 | 10:45 a.m. - 12:13 p.m. | West Hall B4 | |
| The Impact of Full Coverage for Preventive Medications After Myocardial Infarction on Recurrent Vascular Events: The Post-MI Free Rx Event and Economic Evaluation (Post-MI FREEE) Trial | POST-MI FREEE: This trial was designed to evaluate the impact of eliminating patient copayments for post-myocardial infarction secondary prevention medications on rates of vascular events, medication adherence and health spending. |
| Pharmacist Intervention to Prevent Hospitalization and Death in Patients with Heart Failure: A Prospective Cluster Randomised Controlled Trial | This trial determines whether primary care based pharmacists can collaborate with family physicians to reduce the health and economic burden of heart failure admissions and mortality, for primary care based patients with all cause all stage heart failure due to left ventricular systolic dysfunction. |
| Testing an Evidence-Based, Individualized Informed Consent Form to Improve Patients' Experiences with PCI | Given known deficiencies of informed consent - despite demands to improve evidence-based, shared medical decision-making - we tested a novel consent form that is individualized to each patient and includes evidence-based outcomes predictions from valid risk-adjustment models. |
| Outcomes of Non-Primary PCI at Hospitals with and Without On-Site Cardiac Surgery: A Randomized Study | The CPORT E project compares the safety and quality outcomes of percutaneous coronary intervention performed at hospitals with and without on-site cardiac surgery. |
| LBCT.03 | 3:45 p.m. - 5:13 p.m. | Chapin Theatre | |
| Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of Celivarone 50, 100 Or 300 Mg OD with Amiodarone as Calibrator for the Prevention of ICD Interventions or Death (ALPHEE) | This trial evaluated the efficacy and safety of celivarone for the prevention of ICD intervention or death. |
| Atrial Fibrillation Catheter Ablation versus Surgical Ablation Treatment: a Multi-center Randomized Clinical Trial | FAST - This randomized clinical trial was designed to establish whether catheter ablation or minimal invasive surgical ablation would be better and/or safer for ablation of AF |
| A Randomized Multicenter Comparison of Radiofrequency Ablation and Antiarrhythmic Drug Therapy as First-Line Treatment in 294 Patients with Paroxysmal Atrial Fibrillation | MANTRA-PAF - A Randomized Multicenter Comparison of Radiofrequency Ablation and Antiarrhythmic Drug Therapy as First-Line Treatment in 294 Patients with Paroxysmal Atrial Fibrillation |
| The Results of the PALLAS Study | This trial was designed to test if dronedarone could reduce major vascular morbidity and mortality in patients with permanent atrial fibrillation and previous vascular disease or multiple risk factors. |
| Tuesday, Nov. 15, 2011 LBCT.04 | 10:45 a.m. - 12:13 p.m. | West Hall B4 | |
| Practice-Based Opportunities for Weight Reduction (POWER) | This trial was designed to test and compare two behavioral weight loss interventions that could be implemented as part of routine medical practice. |
| Comparison of the Progression of Coronary Atherosclerosis for Two High Efficacy Statin Regimens with Different HDL Effects: SATURN Study Results | SATURN - This trial was designed to evaluate whether distinct effects on both atherogenic and protective lipid parameters with different statins will translate to differences in growth of plaque. |
| Lipid-Modulating Effects of Evacetrapib, a Novel CETP Inhibitor, Administered as Monotherapy or in Combination with the Most Commonly-Used Statins | This trial was the first to evaluate the impact of a novel CETP inhibitor on lipids on a background of all statins currently used in clinical practice. |
| Extended-Release Niacin Does Not Reduce Clinical Events in Patients with Established Cardiovascular Disease Whose LDL-Cholesterol is Optimally Controlled with Statin Therapy: Results from the AIM-HIGH Trial | AIM-HIGH evaluated the use of extended release niacin in patients with history of atherosclerotic CVD and dyslipidemia (low HDL-C, high triglycerides) to reduce rate of major CV events: cardiac death, MI, ischemic stroke, hospitalization for ACS or symptom-driven coronary/cerebral revascularization; all participants were treated to target with statins. |
| Wednesday, Nov. 16, 2011 LBCT.05 | 10:45 a.m. - 12:13 p.m. | Room W415 (Valencia Ballroom) | |
| Randomized Trial of Early Surgery versus Conventional Treatment for Infective Endocarditis (EASE) | The EASE trial is the first randomized trial comparing early surgery with conventional treatment in infective endocarditis patients with high embolic risks. |
| Claudication Treatment Comparative Effectiveness: 6 Month Outcomes From the CLEVER Study | CLEVER - Comparative effectiveness study designed to assess effectiveness of medications, supervised exercise, and stent revascularization for individuals with claudication and aortoiliac peripheral arterial disease |
| Colchicine Reduces Post-Operative Atrial Fibrillation. Results of the COPPS Atrial Fibrillation Study | Aim of the COlchicine for the Prevention of the Post-Pericardiotomy Syndrome (COPPS) POAF study is to test the efficacy and safety of colchicine for the prevention of post-operative atrial fibrillation (POAF). This is the first study to test the hypothesis that colchicine may prevent POAF. |
| ELEVATE-TIMI 56: Escalating Clopidogrel by Involving a Genetic Strategy-TIMI 56 | ELEVATE-TIMI 56: This is a multicenter, randomized, double-blind trial designed to test if higher maintenance doses of clopidogrel (up to 300 mg daily, IND107635) can overcome diminished platelet inhibition due to reduced-function CYP2C19 genotypes. |
| CLINICAL SCIENCE: SPECIAL REPORTS | View in Program Planner | |
| Monday, Nov. 14, 2011 CS.01 | 9:00 a.m. - 10:15 a.m. | Chapin Theater | |
| Results From LateTIME: A Randomized, Placebo Controlled Trial of Intracoronary Stem Cell Delivery Two to Three Weeks Following Acute Myocardial Infarction | LateTIME is a randomized, double-blind, placebo-controlled trial investigating safety and therapeutic efficacy of intracoronary autologous BMCs delivered 2-3 weeks following successful reperfusion with primary PCI in patients with new post-MI LV dysfunction. |
| A Phase II Dose-Escalation Study of Allogeneic Mesenchymal Precursor Cells in Patients with Ischemic and Nonischemic Heart Failure | This study describes preliminary results of the first use of allogeneic mesenchymal precursor cells in patients with heart failure. |
| Cardiac Extracorporal Shock Wave Application to Enhance the Efficiency of Intracoronary Cell Therapy in Chronic Heart Failure - Results of the Randomized, Double-Blind, Placebo-Controlled CELLWAVE Trial | The CELLWAVE trial was designed to demonstrate improved recovery of LV function by combining targeted extracorporal shock wave application with subsequent intracoronary application of bone marrow-derived mononuclear cells in patients with chronic post-infarction heart failure. |
| The CADUCEUS (CArdiosphere-Derived aUtologous Stem CElls to Reverse ventricUlar dySfunction) Trial | CADUCEUS - this first-in-human trial tests the safety and efficacy of autologous heart-derived cells in patients with left ventricular dysfunction after myocardial infarction. |
| CS.02 | 10:45 a.m. - 12:00 p.m. | Chapin Theater | |
First Human Use of an Allogeneic Tissue Engineered Vascular Graft | This is a first in man study describing how donated skin cells generated blood vessels which were then used for dialysis in diabetic patients. |
| ABSORB Cohort B Trial: Two Year OCT Results of the ABSORB Bioresorbable Everolimus Eluting Vascular Scaffold | The ABSORB trial was designed to assess the safety and performance of the ABSORB Bioresorbable Everolimus Eluting Vascular Scaffold in the treatment of patients with a maximum of two de novo native coronary artery lesions located in two different major epicardial vessels. |
| Intracoronary Infusion of Bone Marrow-Derived Mononuclear Cells in Acute Myocardial Infarction: 5 Year Clinical Outcome and MRI Data of the Randomized, Double-Blind, Placebo-Controlled REPAIR-AMI Trial | This study will present the 5 year outcomes of patients who following an AMI had stem cells injected into their myocardium in an effort to reduce the size of the MI. |
| Development of a Long-Term Superficial Device for Partial Circulatory Support | This will describe efforts to develop a long term cardiac assist device for patient use. |
